

Respiratory

RESEARCH REVIEW™

Making Education Easy

Issue 193 – 2022

In this issue:

- Deep learning for detecting common chest x-ray abnormalities
- Females have better survival after lung cancer surgery
- Secondary care barriers and enablers to early lung cancer diagnoses among Māori
- Chronic effects of high PM_{2.5} on lung cancer
- Providing smoking cessation resources during shared decision-making for lung cancer screening
- Lung cancer probability and outcomes of subsolid nodules detected on low-dose CT
- ctDNA for identifying somatic mutations and tracking tumour evolution in NSCLC
- Breast and lung effusion survival score models: improving survival prediction
- Thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions
- Indigenous perspectives on breaking bad news

Abbreviations used in this issue

ctDNA = circulating tumour DNA
HR = hazard ratio
LDH = lactate dehydrogenase
NSCLC = non-small-cell lung cancer
OR = odds ratio
PM_{2.5} = particulate matter with an aerodynamic diameter ≤2.5µm



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

Welcome to the first Respiratory Research Review of 2022 with the topic of lung cancer.

Lung cancer continues to be the leading cause of cancer death, making up 25% of all cancer deaths. More people die of lung cancer than of colon, breast and prostate cancer combined. About 6% of men and women will be diagnosed with lung cancer during their life time, with the average age of 70 years. A French group looking at 1329 patients aged less than 50 years who had undergone resection for primary lung cancer found that almost half reported cannabis combined with tobacco smoking. Many had significant emphysema and more surgical complication: their title, '[Cannabis use and lung cancer: time to stop overlooking the problem](#)'.

Despite advancing therapies like immunotherapy, the 5-year survival for lung cancer is only about 18%, much lower than for breast cancer (90%), colorectal cancer (65%) and prostate cancer (99%). Patients with lung cancer, like all cancer patients, are overwhelmed with anxiety, depression and fear. Lung cancer patients have the additional burden of living with the stigma of it being self-induced. This stigma is a possible dark side of Smokefree campaigns. Two colleagues report in their [editorial](#) 'Lung cancer – why the stigma? And what can be done?' that half of all lung cancer patients report experiencing stigma from healthcare providers. Colleagues from New York developed an [empathy communication skills training module](#) particularly tailored for those providing cancer care.

Our colleagues from the Peter MacCallum Cancer Centre in Melbourne, together with the Massachusetts General Hospital in Boston, have [published](#) an authoritative Lung Cancer seminar in The Lancet. They reviewed the evidence for screening, the histological classification and the most common ontogenetic mutations. Alesha Thai and colleagues have generated a table of outcomes comparing the use of targeted and immune checkpoint inhibitors to treat lung cancer. The table comparing historical platinum-based approaches with targeted therapies, and immune therapy in metastatic NSCLC (non-small-cell lung cancer) shows encouraging impacts on survival rates. Actually, immunotherapy for NSCLC is becoming common enough that some Canadian colleagues, including a former medical student of mine, wrote a [review](#), matching the immunotherapeutic approach to the patient characteristics, like patients with poor performance status, patients on steroids, patients with pre-existing autoimmune conditions, and rechallenging with immune checkpoint inhibitors after side effects.

Probably more relevant for hospital-based doctors is the European Respiratory Society's [statement](#) on thoracic ultrasound. It naturally covers its efficacy in the management of malignant pleural effusions. It is rather comprehensive and recalls its use in the assessment of the chest wall, pneumothorax, interstitial lung disease, lung consolidation and the diaphragm. The statement comments on training. Training in thoracic ultrasound does not quite compare, as yet, with the evidence published a systematic literature [review](#) on the 'Methodological quality of guideline for training or competency processes for basic point-of-care echocardiography in critical care'. Closer to our own field is the [review](#): 'Avoid the trap – nonexpanding lung', which differentiated between lung entrapment and trapped lung, with diagnostic algorithms and suggestions for management/treatment.

Thank you for your continued interest in Research Review publications. If you wish to start the year off with a light discussion, you may wish to take the quiz prepared by our American colleagues to estimate the treatment effect of anticoagulation in atrial fibrillation, management of mild hypertension, benefit of osteoporosis prophylaxis and treatment of hypercholesterinaemia. The free five-item questionnaire and detailed answers are in the appendix, the performance of our American colleagues can also be found in this [article](#) on the 'Clinician conceptualization of the benefits of treatments for individual patients'.

With best wishes for a safe, successful and solid year 2022.

Kind regards,

Professor Lutz Beckert

lutzbeckert@researchreview.co.nz

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Independent commentary by Professor Lutz Beckert

Professor Lutz Beckert is the Associate Dean Medical Education with the University of Otago, Christchurch. He is also a Respiratory Physician at Canterbury District Health Board with particular clinical interests in interstitial lung disease, pulmonary vascular disease, respiratory physiology and COPD (chronic obstructive pulmonary disease). Lutz is happy to be contacted to discuss research ideas either as a sounding board or with the view of future collaborations.



Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs

Authors: Nam JG et al.

Summary: These researchers developed DLAD-10, a deep learning algorithm for detecting ten common abnormalities on chest x-ray, using data from 146,717 training radiographs obtained from 108,053 patients. External validation of DLAD-10 revealed area under the receiver operating characteristic curve values of 0.895–1.00 in a same-day CT-confirmed (normal:abnormal 53:147) dataset and 0.913–0.997 in an open-source (normal:abnormal 339:334) dataset when compared with three radiologists. Compared with radiologists (pooled), DLAD-10 correctly classified significantly more critical abnormalities (95.0% vs. 84.4% [$p=0.01$]). Simulated reading tests for patients presenting to an ED revealed that when aided by DLAD-10, pooled readers detected significantly more abnormalities, both critical (70.8% vs. 29.2% [$p=0.006$]) and urgent (82.7% vs. 78.2% [$p=0.04$]). DLAD-10 assistance also led to reductions in mean time-to-report for critical and urgent radiographs (640.5 vs. 3371.0 sec and 1840.3 vs. 2127.1 sec, respectively [$p<0.01$]) and mean interpretation time (20.5 vs. 23.5 sec [$p<0.001$]).

Comment: Deep learning is a branch of artificial intelligence that is particularly good at identifying patterns in and mapping chest abnormalities according to categories/diagnoses. These Korean researchers trained an algorithm on almost 150,000 radiographs to detect diagnoses like pneumothorax, mediastinal widening, pneumoperitoneum, nodule/mass, consolidation, pleural effusion, linear atelectasis, fibrosis, calcification and cardiomegaly. In a routine setting, the deep learning algorithm outperformed radiologists. However, in the emergency setting, the radiologists picked up more critical diagnoses. In their [editorial](#), Lucio Calandriello and Simon Walsh give us the **bottom line: deep learning can provide decision support for radiologists and are almost ready for clinical practice.**

Reference: *Eur Respir J* 2021;57:2003061
[Abstract](#)

Consider switching your SPIRIVA Handihaler (dry powder) patients to SPIRIVA RESPIMAT Soft Mist Inhaler*^{1,2}

*Treatment decisions, including inhaler choice, should be based on individual assessment of each patient³



SPIRIVA is fully funded[§]

The same SPIRIVA you trust[†] with the easy inhalation of RespiMat^{†1,2,4-8}

[†]Over 15 years prescribing experience in New Zealand and more than 31 million patient-years of use worldwide^{2,8} [‡]Targeted inspiratory flow rate is 30 L/min⁹, so only a slow, deep breath is required¹.

To request COPD resources for your patients or clinic [Click Here](#)

References: 1. SPIRIVA RespiMat Approved NZ Data Sheet, July 2019. 2. SPIRIVA Approved NZ Data Sheet, March 2019. 3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of COPD – 2020. Available at: <https://goldcopd.org/gold-reports>. Accessed January 2020. 4. Hodder R, Price D. *Int J COPD* 2009;4:381–90. 5. Schürmann W et al. *Treat Respir Med* 2005;4:53–61. 6. Kardos P et al. *Eur Respir J* 2005;26(Suppl 49):338s. 7. Wachtel H et al. *Pulm Ther* 2017;3:19–30. 8. Halpin D et al. *Int J COPD* 2015;10:239–59. 9. Pitcairn G et al. *J Aerosol Med* 2005;18:264–72.

Before prescribing, please review the full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>. SPIRIVA® (tiotropium) 18 mcg powder for inhalation, capsules and SPIRIVA® RESPIMAT® (tiotropium) 2.5 micrograms/puff, solution for inhalation ABRIDGED PRESCRIBING INFORMATION. INDICATIONS: Long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Reduces frequency of exacerbations, improves exercise tolerance and health-related quality of life. **DOSAGE:** SPIRIVA capsules: Inhalation of the contents of one capsule, once daily with the Handihaler device, at the same time of day. SPIRIVA RESPIMAT: Two puffs once daily at the same time each day. Do not use more than once daily. Cartridges to be used only with RESPIMAT inhaler. **CONTRAINDICATIONS:** Hypersensitivity to atropine or its derivatives, or to any component of the product. **WARNINGS AND PRECAUTIONS:** SPIRIVA capsules and SPIRIVA RESPIMAT: Should not be used for the initial treatment of acute episodes of bronchospasm, immediate hypersensitivity reactions, narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, inhalation-induced bronchospasm, moderate to severe renal impairment (CrCL ≤ 50 mL/min), pregnancy, lactation, children. SPIRIVA capsules: Avoid powder entering eyes. Contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose/galactose malabsorption should not take this medicine. SPIRIVA RESPIMAT: Should not be used for the relief of acute symptoms. Cardiac rhythm disorders. Avoid solution or mist entering eyes. **ADVERSE EFFECTS:** Common: Dry mouth (usually mild) Serious: glaucoma, supraventricular tachycardia, atrial fibrillation, tachycardia, bronchospasm (including inhalation-induced), gastroesophageal reflux disease, constipation, intestinal obstruction incl. ileus paralytic, hypersensitivity reactions (including immediate reactions), urinary retention, urinary tract infection. Others, see full Data Sheet. **INTERACTIONS:** Co-administration with other anticholinergic drugs. **ACTIONS:** Tiotropium is a specific antimuscarinic agent (anticholinergic), which provides significant and long-acting (24 hours) bronchodilation in patients with COPD, with no evidence of tolerance. The long duration is due to the high potency and slow receptor dissociation from the muscarinic M3 receptor. Bronchodilation is primarily a local effect (on the airways), not a systemic one. **PRESCRIPTION MEDICINE** SPIRIVA® and SPIRIVA® RESPIMAT® are fully funded – Pharmaceutical Schedule, www.pharmac.govt.nz. Prescription must be endorsed that the patient has been diagnosed as having COPD using spirometry. BOEHRINGER INGELHEIM (N.Z.) Ltd, Level 3, 2 Osterley Way, Manukau, Auckland 2104. Spiriva® and RespiMat® are registered trademarks of Boehringer Ingelheim. Version date: 01 July 2021. PC-NZ-100107 TAPS PP6098



For more information, please go to www.medsafe.govt.nz

[CLICK HERE](#)
to read previous issues of
Respiratory Research Review

KINDLY SUPPORTED BY



KEYTRUDA®
(pembrolizumab)

A KEY TO MORE TOMORROWS IS POSSIBLE

for your patients with metastatic non-small cell lung cancer
(mNSCLC) in the first-line treatment setting whose tumours are:^{1*}

Non-squamous

with no EGFR or ALK genomic tumour aberrations



Hypothetical patient

* In KEYNOTE-189 study, KEYTRUDA + plat/pem demonstrated superior OS vs. placebo + plat/pem; number of events were 127/410 (31%) vs. 108/206 (52%) respectively, HR 0.49, 95% CI: 0.38-0.64, p<0.00001; co-primary endpoint PFS was also met; median follow-up of 10.5 months.¹ The most common grade 3-5 AEs (≥2%) reported in the KEYTRUDA arm included anaemia, neutropenia, thrombocytopenia, fatigue, asthenia, diarrhoea, vomiting, dyspnea, nausea, rash, pneumonitis, severe skin reactions.²

[VIEW STUDY DESIGN](#)

Squamous



Hypothetical patient

* In KEYNOTE-407 study, KEYTRUDA + carbo + pac/nab-pac demonstrated superior OS vs. placebo + carbo + pac/nab-pac; number of events were 85/278 (31%) vs. 120/281 (43%) respectively, HR 0.64, 95% CI: 0.49-0.85, p=0.0008; median follow-up of 7.8 months.^{1,3} The most common grade 3-5 AEs (≥2%) reported in the KEYTRUDA arm included anaemia, neutropenia, thrombocytopenia, fatigue, diarrhoea, decreased appetite, asthenia, arthralgia, pneumonitis, colitis, hepatitis.⁴

[VIEW STUDY DESIGN](#)

Y | CONSIDER KEYTRUDA
FOR YOUR ELIGIBLE PATIENTS WITH mNSCLC¹

KEYTRUDA® (pembrolizumab) is a Prescription Medicine.

Please review the KEYTRUDA Data Sheet before prescribing. The Data Sheet is available at www.medsafe.govt.nz.

INDICATIONS: In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic non-small cell lung carcinoma (NSCLC), with no EGFR or ALK genomic tumour aberrations. In combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of metastatic squamous NSCLC.

CONTRAINDICATIONS: None.

PRECAUTIONS: Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, nephritis, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis, severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis), uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (including exacerbation), myelitis, vasculitis, myocarditis, sclerosing cholangitis, solid organ transplant rejection and acute graft-versus-host-disease (can be fatal) with a history of allogeneic HSCT, higher than expected frequencies of Grades 3 and 4 ALT and AST elevations in advanced RCC when used in combination with axitinib, increased mortality when in combination with dexamethasone and a thalidomide analogue in multiple myeloma (not indicated), severe infusion reactions including hypersensitivity and anaphylaxis. Severe and fatal cases of immune-mediated adverse reactions have occurred. Immune-related adverse reactions have occurred after discontinuation of treatment with KEYTRUDA and can affect more than one body system simultaneously. Monitor thyroid and liver function. For management of immune-mediated adverse events, see Data Sheet. Limited data in patients with active infections and with history of severe adverse reaction to ipilimumab – use caution. Only indicated in paediatric patients with cHL and MSI-H/dMMR cancers. The safety and effectiveness in paediatric patients with MSI-H CNS cancers have not been established. No data in severe renal impairment, or moderate or severe hepatic impairment. Pregnancy (Category D). See Data Sheet for further information.

ADVERSE EVENTS: *Monotherapy:* pneumonitis, colitis, diarrhoea, pyrexia, fatigue, pruritus, rash, nausea, hypothyroidism, hyperthyroidism, adrenal insufficiency, hepatitis, hypophysitis, nephritis, type 1 diabetes mellitus, arthralgia, cough, back pain, vitiligo, lymphopenia, hypertriglyceridemia, abdominal pain, hyponatremia, hyperglycaemia, hypocalcaemia, increased AST and ALP, anaemia, dyspnea, constipation, vomiting; *Combination (where not already listed under Monotherapy):* alopecia, asthenia, decreased neutrophil count, neutropenia, mucosal inflammation, stomatitis, decreased white blood cell count; See Data Sheet for adverse events relevant to the other indication(s).

[READ MORE](#)

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland.
NZ-LAM-00018 TAPS DA 2251PC First issued December 2021 essence MSD10637



For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

Sex and survival after surgery for lung cancer

Authors: Sachs E et al.

Summary: Prognoses were compared between women versus men who had undergone pulmonary resection for lung cancer in this Swedish population-based observational cohort study (n=6356). Compared with men, women had a lower mortality risk following pulmonary resection (HR 0.73 [95% CI 0.67, 0.79]), with respective absolute 1-, 5- and 10-year survival differences of 3.0%, 10% and 12% and a restricted mean survival time difference at 10 years of 0.84 years; consistent findings were evident across several subgroups.

Comment: Currently, the incidence of lung cancer is falling twice as fast in men than in women, reflecting the delay in tobacco uptake and cessation by women ([Lancet 2021;398:535–54](#)). This retrospective study based on more than 6000 lung cancer patients in Sweden provides some good news for women. Women have a better survival rate after resection of a lung cancer, even when corrected for histological type, stage, comorbidities, lifestyle factors, socioeconomic status and age. Their survival benefit is 3% at 1 year and 12% at 10 years. **Bottom line: while lung cancer diagnoses are still increasing, resection of early-stage cancer is successful in women.**

Reference: *Chest* 2021;159:2029–39

[Abstract](#)

Hā Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Māori communities

Authors: Kidd J et al.

Summary: Improved communication and understanding of cultural needs is needed within healthcare services involved in the secondary care of lung cancer in Māori communities. A kaupapa Māori approach was used to carry out nine community hui and nine primary healthcare provider hui in five rural localities in the Midland region of NZ. Barriers and enablers in specialist services and treatment related to access to care, engagement with specialists, communication with specialist services and cultural values and respect. Barriers and enablers in the whānau journey related to agency and the impact on whānau. Findings also highlighted the active efforts made by whānau to foster health literacy in future generations.

Comment: Previously, we cited some of Sue Crengle's work that lung cancer mortality for Māori is almost three times greater than for non-Māori (Respiratory Research Review [Issue 181](#)). The Te Huataki Waiora School of Health research group provides insights from the midland region, with researchers using the kaupapa Māori research approach. They ran nine hui/ focus groups of community members and primary care providers. The community groups included cancer patients and whānau. Themes identified included access to care, engagement with specialists, communication with specialists, cultural value and respect, and the whānau journey. **Bottom line: the urgency to understand cultural needs and to improve communication are key findings, as are Māori resilience and whānau advocacy.**

Reference: *BMC Cancer* 2021;21:121

[Abstract](#)

Chronic effects of high fine particulate matter exposure on lung cancer in China

Authors: Li J et al.

Summary: Response patterns of lung cancer associated with high exposure to PM_{2.5} were reported for a cohort of 118,551 Chinese individuals followed from 1992 to 2015. This cohort experienced 844 incident lung cancers over 915,053 person-years of follow-up, causing 701 subsequent deaths. Nonlinear exposure-response curves were seen for lung cancer associated with PM_{2.5} exposure, with steeper slopes occurring at higher concentrations. Compared with participants exposed to the lowest PM_{2.5} quintile, the lung cancer risk was increased across the second to fifth quintiles (respective adjusted HRs 1.44 [95% CI 1.10, 1.88], 1.49 [1.12, 1.99], 2.08 [1.42, 3.04] and 2.45 [1.83, 3.29]), as was the likelihood of lung cancer-associated mortality (1.83 [1.33, 2.50], 1.80 [1.29, 2.53], 2.50 [1.62, 3.86] and 2.95 [2.09, 4.17]).

Comment: This time last year we witnessed the Australian bush fires. I recall the limited evidence of their adverse effects on cardiac disease, airways disease and lung cancer. This group of Chinese researchers used participants from cardiovascular epidemiology registries and correlated clinical outcomes with PM_{2.5}. PM_{2.5} pollution data were obtained from US satellite images and ground-based monitors. More than 100,000 people were followed and 844 developed lung cancer. **Bottom line: air pollution with fine particles is a risk factor for developing lung cancer. Large gains can be made with a small improvement in air quality.**

Reference: *Am J Respir Crit Care Med* 2020;202:1551–9

[Abstract](#)

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

RACP MyCPD Program participants can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.

Please [CLICK HERE](#) to download CPD Information

Each month we highlight a particularly excellent paper with our butterfly symbol.



Provision of smoking cessation resources in the context of in-person shared decision-making for lung cancer screening

Authors: Shen J et al.

Summary: This was a US-based retrospective study of 423 current smokers (70% male) participating in initial lung cancer screening shared decision-making. Of the study participants, documentation consistent with shared decision-making was evident for only 26%, only 39% had received ≥1 smoking cessation resource, and only 5% received both counselling referrals and medication. A multivariate analysis revealed a Charlson Comorbidity Index score of ≥2 was associated with a significantly lower likelihood that any smoking cessation resource had been provided (OR 0.53 [95% CI 0.31, 0.81]), as was ordering by a provider other than the participant's primary care provider or specialist (0.55 [0.32, 0.96]).

Comment: In 2021, articles on lung cancer screening were amongst the most downloaded articles ([JAMA 2021:325:962–70](#)) and we may engage in a [focussed lung cancer screening trial](#) in NZ in 2022. These US-based researchers remind us that any contact with the health service is an opportunity for smoking cessation. However, in their survey of 400 men participating in lung cancer screening in Seattle, only 17% were offered a prescription for tobacco addiction and only 5% received counselling and medication referral. Steven Zeliadt's title of his accompanying [editorial](#) gives us the **bottom line: smoking cessation resources can and should be integrated into lung cancer screening.**

Reference: *Chest* 2021;160:765–75

[Abstract](#)



Breo:

25% more patients had improved asthma control vs. other ICS/LABAs in everyday practice¹

When stepping up from an ICS, Breo (FF/VI 100/25 mcg) is recommended²



Breo is well tolerated. Most common adverse events are nasopharyngitis and headache.



BREO ELLIPTA

fluticasone furoate / vilanterol

References: 1. Woodcock A et al. *Lancet* 2017;390:2247–2255. 2. GlaxoSmithKline New Zealand. Breo Ellipta Data Sheet. GSK NZ; 2018. Available at <https://medsafe.govt.nz/profs/datasheet/b/breoelliptainhalation.pdf>.

Breo Ellipta (fluticasone furoate/vilanterol trifenatate inhaler 100/25mcg per inhalation) is a **Prescription Medicine**. Breo Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta₂ agonist and inhaled corticosteroid) is appropriate. Breo Ellipta is also indicated for symptomatic treatment of adult patients with COPD with a FEV₁ <70% predicted normal (post-bronchodilator) and with an exacerbation history. **Breo Ellipta 100/25mcg is a fully funded medicine. Breo Ellipta 200/25mcg is a private purchase medicine (dose indicated in asthma only); a prescription charge will apply. Maximum Daily Dose:** In asthma adults and adolescents aged 12 years and over: One inhalation once daily. In COPD adults aged 18 years and over: One inhalation once daily. **Contraindications:** Patients with severe milk-protein allergy or those who have hypersensitivity to fluticasone furoate, vilanterol or any excipients. **Side Effects:** Candidiasis of mouth and throat, headache, nasopharyngitis, oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia, upper

respiratory tract infection, bronchitis, influenza, abdominal pain, arthralgia, back pain, pyrexia, fractures. **Warnings and Precautions:** Not to be used for the treatment of acute asthma symptoms or an acute COPD exacerbation, for which a short-acting bronchodilator is required. Paradoxical bronchospasm may occur. Use care when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole), beta-blockers and in patients with severe cardiovascular disease, hepatic impairment, pulmonary tuberculosis, or in patients with chronic untreated infections. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. The incidence of pneumonia and fractures in patients with asthma was uncommon. Before prescribing Breo Ellipta, please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at www.medsafe.govt.nz. Breo and Ellipta are registered trade marks of the GlaxoSmithKline group of companies. Breo Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA2028AM-PM-NZ-FFV-ADVT-20JUN0006.**

For more information, please go to www.medsafe.govt.nz

Lung cancer probability and clinical outcomes of baseline and new subsolid nodules detected on low-dose CT screening

Authors: Kim YW et al.

Summary: These researchers reported on the characteristics of subsolid nodules detected on low-dose CT in 22,631 never-smoker and 27,501 ever-smoker South Korean adults. There were 5116 pure ground-glass opacity nodules and 1609 part-solid nodules detected in 4545 participants, with a higher overall subsolid nodule incidence in never- versus ever-smokers (10.7% vs. 7.7% [$p<0.001$]). Among the subsolid nodules with follow-up CT scans ($n=4918$), 30.0% of baseline subsolid nodules and 78.9% of new subsolid nodules resolved spontaneously. Among biopsied subsolid nodules ($n=293$), 77.5% were lung cancer (all adenocarcinomas except one). There was no significant difference between baseline and new cancerous subsolid nodules for pathological invasiveness or initial stage. New subsolid nodule detection at follow-up screening was significantly associated with lower likelihoods of lung cancer (OR 0.26 [95% CI 0.14, 0.49]) and overall growth (0.39 [0.26, 0.59]), and a greater likelihood of resolution (6.30 [5.09, 7.81]).

Comment: One of the unsettling events during nodule surveillance of patients is the occurrence of new nodules on the CT scan while monitoring old nodules. This Korean study follows more than 50,000 subjects who underwent CT screening to assess the incidence, characteristics and nodules occurring in never-smokers during lung cancer screening. Nodules occurred during the screening in 10% of never-smokers, almost 80% resolved and only 1.1% turned out to be ultimately malignant. **Bottom line: at least in an Asian population, new nodules have a low probability of lung cancer, and may need less aggressive follow-up.**

Reference: *Thorax* 2021;76:980–8

[Abstract](#)

Usefulness of circulating tumor DNA in identifying somatic mutations and tracking tumor evolution in patients with non-small cell lung cancer

Authors: Roosan MR et al.

Summary: The usefulness of analysing ctDNA versus solid tumour biopsies was explored in a retrospective evaluation of 370 adults with NSCLC. Among 473 ctDNA samples analysed, 1688 somatic mutations were detected, with 177 of the samples showing ≥ 1 actionable mutation for currently available US FDA-approved NSCLC therapies. There was co-occurrence of *MET* and *CDK6* amplifications with *BRAF* amplifications (false discovery rate, <0.01), and gene-level mutations were mutually exclusive in *KRAS* and *EGFR* (false discovery rate, 0.0009). An association between low cumulative percentage ctDNA levels and longer PFS was identified (HR 0.56 [95% CI 0.37, 0.85]). Patients with a *BRAF*, *PIK3CA* or *KRAS* mutation had significantly shorter OS (respective HRs for death, 2.35 [95% CI 1.24, 4.6], 2.77 [1.56, 4.9] and 2.32 [1.30, 4.1]). There was gene-level concordance of 93.8%, whereas a positive concordance rate of 41.6% was seen. ctDNA analyses revealed more targetable gene mutations than tissue biopsy samples. Repeated ctDNA samples revealed treatment response and tumour evolution over time.

Comment: NSCLC accounts for 85% of all lung cancer cases and is increasingly treated with targeted therapies (*JCO Oncol Pract* 2021;17:465–71). This American research group is challenging the gold-standard role of a tissue biopsy. Tissue biopsies are costly, painful and risky, and they are difficult to repeat. We have previously reviewed (Respiratory Research Review [issue 120](#)) the role of cell-free DNA (also known as 'liquid biopsy') in estimating the cancer burden in lung cancer. These researchers used ctDNA from 370 patients with lung cancer and compared the outcomes with results from tissue biopsies. **Bottom line: ctDNA may offer additional opportunities to identify targetable mutations beyond tissue biopsy samples.**

Reference: *Chest* 2021;160:1095–107

[Abstract](#)

Breast and lung effusion survival score models: improving survival prediction in patients with malignant pleural effusion and metastasis

Authors: Molina S et al.

Summary: The ability of a continuous risk-prediction model to predict survival of patients with malignant pleural effusions and known metastatic disease was explored in a retrospective cohort of patients who underwent thoracentesis at a single centre during 2014–2017. Discrete (LENT-D) and continuous (LENT-C) models were generated using LENT variables, for which predictors' performances were assessed. The model was developed using data from a cohort of 562 patients and validated in a cohort of 727 patients. Significant interactions were seen between cancer type and neutrophil-to-lymphocyte ratio ($p<0.0001$), pleural fluid LDH level ($p=0.029$) and bilateral effusion ($p=0.002$). Disease-specific models for lung, breast and haematological malignancies had respective C-statistic values of 0.72, 0.72 and 0.62, and the combined model's C-statistic value was 0.67. In contrast, both LENT-D and LENT-C underperformed (respective C-statistic values, 0.60 and 0.65).

Comment: In 2005, we reported on the LENT score to estimate the survival of patients with malignant pleural effusions (Respiratory Research Review [issue 108](#)). The simple LENT score utilises LDH level, ECOG (Eastern Cooperative Oncology Group) status, blood neutrophil-to-lymphocyte ratio and tumour type to predict survival. These Mexican and US authors used data from 500 patients to design, and data from 700 patients to validate BLESS (Breast and Lung Effusion Survival Score). As the accompanying [editorial](#) points out, this is the first tumour-specific survival score. **Bottom line: the BLESS score provides more accurate survival estimates for breast and lung cancer patients with malignant pleural effusions.**

Reference: *Chest* 2021;160:1075–94

[Abstract](#)

Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE)

Authors: Psallidas I et al.

Summary: Adults with malignant pleural effusion requiring talc pleurodesis were randomised to thoracic ultrasonography-guided care ($n=159$) or standard care ($n=154$) in this open-label trial. Compared with standard care, thoracic ultrasonography-guided care was associated with a significantly shorter median length of hospital stay in the intent-to-treat population (2 vs. 3 days [$p<0.0001$]) and was noninferior for pleurodesis failure at 3 months in the per-protocol population (29.7% vs. 31.2%). The intervention group also had a shorter mean time to chest tube removal (2.4 vs. 3.1 days [$p=0.0057$]) and there was no significant between-group difference for all-cause mortality, symptom scores or quality of life scores, except for a lower EQ-5D visual analogue scale score at 3 months in the standard care group. Thoracic ultrasonography-guided care was cost effective when compared with standard care.

Comment: About 15% of patients with lung cancer develop a malignant pleural effusion, and about 80% require a therapeutic intervention. The success rate of pleurodesis is between 50% and 80%, and current guidelines suggest that a chest drain can be removed following talc slurry if it drains less than 500mL in 24 hours. These UK authors randomised about 300 patients to standard treatment or with thoracic ultrasound-guided care. Gary Lee wrote the most learned [editorial](#), appreciating the effort of providing an evidence base for talc pleurodesis and pointing out shortcomings. **Bottom line: ultrasound-guided care reduced the hospital stay without reducing the success rate.**

Reference: *Lancet Respir Med*; Published online Oct 8, 2021

[Abstract](#)

Indigenous perspectives on breaking bad news: ethical considerations for healthcare providers

Authors: Cassim S et al.

Summary: The experiences of Māori patients with lung cancer and their whānau in receiving bad news were collected via 23 semistructured interviews and nine focus groups in four districts in the Midland region of NZ. Best practice included understanding the centrality of the healthcare provider-patient relationship and whānau ties in the healthcare journey, as well as providing patients with the full range of viable treatment options, including hope, clear advice and guidance. The study findings hold implications for providing culturally safe and humanistic cancer care when breaking bad news to Māori and indigenous patients.

Comment: Only 15% of patients with lung cancer are diagnosed early enough to consider curative treatment options. Breaking bad news is part of the daily practice of dealing with lung cancer patients. The Te Huataki Waiora School of Health group used Māori researchers and Māori tikanga to interview Māori patients and their whānau about ethical implications of receiving bad news. Māori patients and whānau appreciated options and clear advice given, hope maintained, analogies, simple language, and the role of whānau being appreciated. **Bottom line: breaking bad news can build on general guidelines; in addition, Māori patients/whānau appreciate anchoring delivery of bad news in a Māori health model.**

Reference: *J Med Ethics* 2021;47:e62

[Abstract](#)